breast cancer

News

AZ and Daiichi to file new breast cancer drug after trial su...

In March AstraZeneca asked investors for $3.5 billion to fund a collaboration with Daiichi Sankyo over a new breast cancer drug – and it looks like the project is on track.

News

T-cells attacking cancer cell illustration of microscopic photos

Genetic test can predict efficacy of chemotherapy in breast ...

Researchers have found that a genetic test can successfully predict whether chemotherapy would be beneficial for patients with the most common type of breast cancer – oestrogen-receptor pos

News

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer – making it the first drug app

News

Real-world data unlocks Ibrance ok in male breast cancer

The FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based on a filing that drew heavily on post-marketing and real-world data.

News

AZ signs multi-billion cancer R&D deal with Daiichi Sankyo

AstraZeneca is to raise $3.5 billion to fund a global development and marketing collaboration with Daiichi Sankyo, for an antibody-drug conjugate and potential new targeted cancer medicine,

News